Evidence map›Paper›PMID 42731861›Full record

ArticleOpen heart2026

Long-term incidence and risk factors of atrial fibrillation after percutaneous patent foramen ovale occlusion: a retrospective cohort study.

Oscar Rommens, Maarten Blondeel, Mathias Maes, Marie-Paule Goidts, Christophe Garweg, Els Troost, Peter Haemers, Tomas Robyns, Alexander Van De Bruaene, Joris Ector and 4 more

Abstract read
In one paragraph

Article in Open heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Oscar Rommens *Cardiology, UZ Leuven, Leuven, Belgium.
Maarten Blondeel *Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
Mathias MaesCardiology, UZ Leuven, Leuven, Belgium.
Marie-Paule GoidtsCardiology, UZ Leuven, Leuven, Belgium.
Christophe GarwegCardiology, UZ Leuven, Leuven, Belgium.
Els TroostCardiology, UZ Leuven, Leuven, Belgium.
Peter HaemersCardiology, UZ Leuven, Leuven, Belgium.
Tomas RobynsCardiology, UZ Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-8676-4874
Alexander Van De BruaeneCardiology, UZ Leuven, Leuven, Belgium.
Joris EctorCardiology, UZ Leuven, Leuven, Belgium.
Rik WillemsCardiology, UZ Leuven, Leuven, Belgium.
Werner BudtsCardiology, UZ Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0001-5850-5413
Pieter De MeesterCardiology, UZ Leuven, Leuven, Belgium.
Bert VandenberkCardiology, UZ Leuven, Leuven, Belgium vandenberkbert@gmail.com.ORCID http://orcid.org/0000-0001-8296-920X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPercutaneous patent foramen ovale (PFO) closure is an established intervention for secondary prevention of cryptogenic stroke. Increasing evidence indicates that the procedure is associated with a risk of new-onset atrial fibrillation (AF). This study aimed to describe the temporal distribution and clinical factors associated with new-onset AF following percutaneous PFO closure.

methodsPatients aged ≥16 years undergoing percutaneous PFO closure between 1999 and 2021 at a tertiary care centre were retrospectively included. New-onset AF was identified through systematic review of electronic health records. Descriptives are presented as median with IQR. Time-to-event analysis was performed using cumulative incidence functions and Cox proportional hazards regression.

resultsAmong 867 patients (median age 51 years (42-58), 47% female), PFO closure was performed for secondary stroke prevention in 86%. During a median follow-up of 11.7 years (6.3-16.8), new-onset AF occurred in 97 patients (11.2%), corresponding to an incidence rate of 1.0 per 100 patient-years. AF diagnoses clustered early after closure, with 26.8% occurring within the first 3 months. In multivariable analysis, higher age at closure (HR 1.05 per year; 95% CI 1.03 to 1.07), larger occluder device size (HR 1.09 per mm; 95% CI 1.03 to 1.16) and any moderate or severe valvular regurgitation (HR 3.70; 95% CI 1.65 to 8.33) were independently associated with new-onset AF.

conclusionsNew-onset AF is common after PFO closure and shows early postprocedural clustering. Increasing age, larger occluder size and valvular regurgitation are independently associated with AF occurrence, underscoring the need for focused rhythm surveillance after closure.

Indexed as

Atrial FibrillationCardiac CatheterizationForamen Ovale, PatentAdultFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk AssessmentRisk FactorsSeptal Occluder DeviceTime FactorsTreatment OutcomeAtrial FibrillationHeart Defects, CongenitalHeart Septal Defects, Atrial

Identifiers

PMID42731861
PMCPMC13583860

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.